VKTX - NASDAQ
Viking Therapeutics, Inc.
$29.33
+0.037%Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
At a Glance
Live SnapshotViking Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Viking Therapeutics, Inc. Cash Flow Statement
VKTX • NASDAQ
| Viking Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||
-359.6M | -110M | -85.9M | -68.9M | -55M | -39.5M | -25.8M | -22.1M | -20.6M | -14.7M | -23.4M | -21.9M | -146.2K | -444.0 | |
431K | 346K | 292K | 291K | 296K | 277K | 260K | 477K | 1.4M | 1.9M | 1M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -392K | -1.3M | -1.8M | -893.5K | 0.0 | 0.0 | 0.0 | |
40.8M | 29.7M | 16.8M | 8.7M | 6.1M | 5.8M | 0.0 | 2.6M | 1.5M | 1.8M | 2.6M | 6.3K | 3.0 | 22.0 | |
-9.3M | -17.2M | -8.1M | 1.3M | 3.9M | 3.9M | 4.6M | -208K | 2.5M | 862.6K | 11.3M | -1.7M | 42.6K | 244.0 | |
49M | 9.4M | 3.5M | 10.2M | -2.9M | 7.7M | -3.8M | 823K | 1.8M | 849.9K | 620.3K | 21.9M | 25.4K | 0.0 | |
-278.7M | -87.8M | -73.4M | -48.4M | -47.6M | -21.8M | -24.8M | -18.8M | -14.8M | -11.1M | -8.7M | -1.6M | -78.2K | -200.0 | |
INVESTING ACTIVITIES | ||||||||||||||
-418M | -1.1B | -478.3M | -121.4M | -168M | -280.6M | -362.4M | -348.2M | -22.5M | -16.9M | -16M | (0.0) | (0.0) | (0.0) | |
759.4M | 560M | 299.2M | 176.2M | 206M | 322.2M | 369.9M | 82.5M | 20.8M | 20M | 2.6M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 54.8K | 0.0 | 0.0 | 0.0 | -265.7K | -1.7K | 3K | -13.5K | 0.0 | 0.0 | 0.0 | |
(341.4M) | -553.4M | -179.1M | (54.8M) | (38M) | (41.6M) | (7.5M) | -265.7M | -1.7M | (3M) | -13.5M | (0.0) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | ||||||||||||||
2.5M | 597.1M | 269.8M | -6.8M | 7.6M | 1.2M | 1M | 296.6M | 22.4M | 11.5M | 25.4M | -2.0 | -2.5K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.8M | -77K | -94.9K | 0.0 | 2.5M | 260.4K | 0.0 | |
(0.0) | (0.0) | (0.0) | -6.8M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -229.0 | -38.0 | -2.0 | -2.5K | (0.0) | |
73.9M | 15.4M | 1.6M | 12.5M | -707K | -296K | -151K | 7.5M | 125.5K | -1.1M | -3.2M | -332.3K | 0.0 | 200.0 | |
76.4M | 612.5M | 271.4M | 4.2M | 6.9M | 950K | 887K | 300.3M | 22.4M | 10.3M | 22.2M | 2.2M | 257.9K | 200.0 | |
CASH FLOW SUMMARY | ||||||||||||||
-8K | -148K | -30K | -258K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
139.1M | -28.8M | 18.9M | 10.3M | -2.7M | 20.7M | -16.4M | 15.8M | 5.9M | 2.3M | 12.7K | 576.2K | 179.6K | 0.0 | |
26.7M | 55.5M | 36.6M | 26.4M | 29.1M | 8.4M | 24.8M | 9M | 3.1M | 768.6K | 755.9K | 179.6K | 0.0 | 0.0 | |
165.8M | 26.7M | 55.5M | 36.6M | 26.4M | 29.1M | 8.4M | 24.8M | 9M | 3.1M | 768.6K | 755.9K | 179.6K | 0.0 | |
-278.7M | -87.8M | -73.4M | -48.4M | -47.6M | -21.8M | -24.8M | -18.8M | -14.8M | -11.1M | -8.7M | -1.6M | -78.2K | -200.0 |
SEC Filings
VKTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 11, 2026 | December 31, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 23, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 22, 2025 | October 22, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 19, 2025 | August 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 23, 2025 | July 23, 2025 | 2025 |
Related Guides
Continue your VKTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.